---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250756"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:12:04.153892+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IN8bio presents INB-619 preclinical data at ACR showing deep B cell depletion with minimal cytokine release

## Summary
- INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.
- INB-619 showed minimal IL-6 secretion at concentrations far lower than marketed TCEs, suggesting reduced CRS risk.
- INB-619 selectively expanded γδ T cells without activating αβ T cells, supporting a safer safety profile.
- Data presented at 2025 ACR Convergence; INB-619 is a potential first-in-class pan-γδ T cell engager targeting CD19.

## SEC filing metadata
- accession: 0001193125-25-250756
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/0001193125-25-250756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/d65132d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250756
- JSON: https://secwatch.observer/filing/0001193125-25-250756.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.